What Counts as Therapeutic Progress and Innovation in Longevity Biotechnology?

Longevity biotechnology is attracting increasing scientific, commercial, and investor interest. The unprecedented clinical success of GLP-1 on multiple age-associated conditions has prompted some to call it the first longevity drug, which has certainly boosted excitement for longevity biotechnology. However, there are disagreements on some core concepts needed for efficiently translating aging research into clinical treatments and development of longevity drugs. A 2024 PNAS Nexus survey led by Vadim Gladyshev found no majority agreement on what aging is, when it begins, what causes it, or what rejuvenation means. The definitions of these core principles will guide choices of therapeutic targets, experimental designs, validation strategies, and clinical endpoints. Identifying which aspect of aging an intervention is intended to change, and selecting measurements that correspond to that objective, are important for developing effective and commercially viable longevity therapies.

I was therefore intrigued by the “Control Laws in Aging and Longevity” publication by Alex Zhavoronkov and Bud Mishra (currently available as a preprint on arXiv) that addresses the translational consequences of this uncertainty. They propose a value control framework built around operational definitions. Specifically, they define aging as the progressive loss of “safe controllability” and biological age as the minimum safe cost of restoring or maintaining function.

Specifically, the authors built the value control framework by asking the following question:

“Given a measured biological state , which intervention , at which dose and duration, in which sequence, under which safety constraints, will move the system into a healthier functional region with acceptable risk and preserved future controllability?”
Id.

In other words, this framework asks not simply whether a biomarker changed, but whether a particular intervention can safely restore defined functions in a particular biological context. I cannot do justice here to the full mathematical and biological depth of the article, but three implications struck me as particularly useful from a patent attorney’s perspective.

First, biomarkers become incomplete observations of an underlying biological state rather than fixed markers of aging itself. This is important when a company must decide whether a biomarker is merely correlated with aging or can support a claim of therapeutic benefit.

Second, success is measured through the restoration or preservation of specified functions. Clinical success can be viewed as the safe restoration or maintenance of defined functions rather than restoring individual biomarkers.

Third, timing and sequence become part of the intervention. The model represents interventions as state-dependent vector fields whose effects may differ according to baseline biology, dose, tissue context, and order of administration. This provides testable predictions. For example, the authors predict that performing senolysis before partial reprogramming will restore function more effectively in fibrotic and inflamed aged tissue than the reverse sequence. This is only one of twenty explicit and falsifiable predictions presented in the article.

Importantly, this value control framework forces researchers and developers to make explicit choices about definitions, measurements, function, treatment context, and safety. For a company, these choices are important for target selection, patient stratification, endpoint design, and product differentiation, and impact how a company defines therapeutic success, differentiates its product, and identifies the technical contribution that may warrant patent protection. The relevant inventions may therefore be defined by:

the biological state in which an agent is beneficial or harmful;
a responsive patient population;
a particular treatment sequence;
a dosing strategy informed by longitudinal measurements; or
functional and safety monitoring of therapies.

In other words, explicit fit-for-purpose definitions can therefore be important for identifying, differentiating, and protecting innovation in longevity biotechnology.

Scientists, company leaders, investors, and counsel working in longevity biotechnology will eventually need to decide what meaningful progress looks like for a therapeutic program, an investment thesis, a regulatory strategy, or a patent portfolio. The control-theory framework supplies a useful lens by which to begin answering that question.

The central claim is that control-value reduction predicts translational success better than Hallmark annotation or biomarker reversal alone. If validated, this provides the missing interventional layer connecting aging biology to rational gerotherapeutic discovery.
View referenced article